Form 4: uniQure CEO Sells Shares Under 10b5-1 Plan

uniQure N.V. CEO Matthew C. Kapusta reported transactions involving the sale of ordinary shares and the acquisition of shares through a stock option, all executed under a pre-arranged 10b5-1 trading plan.

Summary

• Matthew C. Kapusta, CEO of uniQure N.V., engaged in several transactions on July 2, 2026.
• He acquired 21,082 ordinary shares through the exercise of a stock option at a price of $19.39 per share.
• Following this acquisition, Kapusta sold 9,200 shares at a weighted average price of $44.43.
• Additional sales included 4,282 shares at a weighted average price of $45.43, and 7,600 shares at a weighted average price of $45.89.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on October 5, 2025.
• After these transactions, Kapusta beneficially owns 519,227 ordinary shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by the CEO, despite being executed under a 10b5-1 plan. While the plan itself is a positive governance practice, the volume of sales can be interpreted as a bearish signal by some investors.

Positives

• The CEO exercised stock options, indicating potential alignment with company performance and long-term incentives.
• The transactions were executed under a Rule 10b5-1 plan, suggesting pre-planned and potentially less market-sensitive trading activity.
• The CEO retains a significant number of shares (519,227) after the reported sales.

Negatives

• The CEO sold a substantial number of shares (21,082 shares acquired and then sold, plus additional sales totaling 21,082 shares), which could be interpreted as a lack of confidence or a need for personal liquidity.
• The sale prices were significantly higher than the stock option exercise price, indicating a profitable transaction for the CEO.

Risks

• The sale of a large number of shares by a key executive could be perceived negatively by the market, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the timing and volume of sales might still raise questions about insider confidence.

Future Outlook

This filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
• The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.10 to $44.80.
• The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.95.
• The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.48 to $46.10.
• The Stock Option vested in full on January 26, 2022.

Industry Context

StockSavvy.ai notes that Form 4 filings by senior executives are common for reporting stock option exercises and subsequent sales, often conducted under pre-established 10b5-1 plans to manage personal finances while adhering to insider trading regulations. The significant difference between the option exercise price and the sale price highlights the potential for executive compensation to be tied to stock performance.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the CEO's sales as a negative signal, potentially impacting share price, despite the 10b5-1 plan. However, the CEO's continued significant ownership may mitigate this concern.
• Employees: The stock option exercise and sale by the CEO could influence employee morale, depending on their perception of the CEO's confidence in the company's future.
• Management: The transactions reflect the standard practice of managing executive compensation and personal finances.

Next Steps

• Monitor future Form 4 filings for any further transactions by Matthew C. Kapusta or other executives.
• Observe the company's stock performance and any related news following these transactions.

Key Dates

Recommendation

The filing reports routine insider transactions under a 10b5-1 plan, which are generally not indicative of a fundamental change in the company's prospects. While the CEO's sale of shares could be a minor concern, the continued substantial ownership and the structured nature of the sale suggest a 'hold' recommendation, pending further company-specific news or financial results.

Keywords

uniQure, QURE, Form 4, SEC Filing, Insider Trading, Stock Options, Share Sales, 10b5-1 Plan, Matthew C. Kapusta, Beneficial Ownership